KLOTHO基因在残余肾模型大鼠中的表达及肾安颗粒的干预作用
|
摘要
肾性骨病(ROD)是慢性肾脏病的主要并发症之一,对患者的生存质量和生存时间有着重要影响。由于肾脏结构和功能的破坏导致肾脏羟化酶系的活性降低,1,25 (OH)2 VitD3的生成相对或绝对不足,PTH的合成与释放失控,是ROD发病的核心环节。Klotho基因(KL)是一种与衰老相关的基因,主要在肾小管、脑脉络膜和甲状旁腺表达,尤以肾皮质远曲小管表达最为强烈。KL基因缺陷鼠可出现一系列与人类“肾精亏虚证”相似的衰老表型变化。研究证实,KL在慢性肾脏病(CKD)肾组织中的表达明显下调,而KL下调可导致骨质疏松,说明KL可能参与发生ROD。另外,成纤维细胞生长因子23(FGF-23)、成骨蛋白-1(BMP-7)、骨保护素(OPG)作为调节骨和肠钙磷转运及骨代谢的激素,在ROD发生过程中起重要作用。那么,KL是否通过调控这些蛋白而参与发生ROD呢?如果能够证实这一假说,将进一步阐明ROD的发病机制并为临床治疗提供新靶点。本研究采用大鼠5/6肾切除残余肾模型,探讨KL基因对FGF-23、BMP-7、OPG的调控机制及肾安颗粒(复方淫羊藿苷、黄芪甲苷、大黄葸醌提取物)的干预作用,预期结果不仅能深化对ROD发病机制的认识,还将在一定程度上揭示中药防治ROD的作用机理。
实验一大鼠残余肾模型的制备
目的：探讨大鼠残余肾并肾性骨病模型的制备方法。
方法：Wistar大鼠48只随机分为正常对照组(A组,n=8)、假手术组(B组,n=8)、造模组(C组,n=32)。经适应性喂养1周后,C组大鼠以戊巴比妥钠腹腔注射麻醉后,行2/3左肾切除,1周后再次行右肾切除。各组大鼠均予正常饮食,A组和B组饮蒸馏水,C组左肾切除术后第二天开始加磷酸二氢钠饮水。各组大鼠造模术后1月眼球取血,测定血红蛋白(HGB)、血肌酐(Scr)、尿素氮(BUN)、血磷(P3+)、血钙(Ca2+)、血清碱性磷酸酶(ALP)、血清全段甲状旁腺激素(iPTH)。取血前1天代谢笼收集24h尿,测尿肌酐(UCr)并计算内生肌酐清除率(Ccr)。
结果：造模术后1月,A、B两组大鼠活泼好动,毛色整齐光亮,体重增加；C组精神萎靡,安静不喜动,毛色杂乱,体重变化不明显。C组HGB与A组和B组比较明显降低(P<0.05)；C组BUN、Scr与A组和B组比较明显升高(P<0.01),C组Ccr与A组和B组比较明显降低(P<0.01)；C组ALP与A组和B组比较明显升高(P<0.05)；C组iPTH与A组和B组比较显著升高(P<0.01)；C组Ca2+与A组和B组比较明显降低(P<0.05)；C组P3+与A组和B组比较明显升高(P<0.01)。A、B两组间以上指标比较无显著性差异(P>0.05)。
结论：5/6肾切除加高磷饮水1月可以导致残余肾模型大鼠钙磷代谢异常,继发PTH升高,提示并发ROD。
实验二残余肾模型钙、磷代谢的变化及肾安颗粒的干预作用
目的：探讨残余肾模型大鼠钙、磷代谢的变化及肾安颗粒的干预作用。
方法：将第一部分实验中的造模组大鼠32只随机分为4组,即模型组(C组,n=8)、阳性药物骨化三醇对照组(D组,n=8)、肾安颗粒中剂量组(E组,n=8)、肾安颗粒高剂量组(F组,n=8)。正常对照组(A组,n=8)、假手术组(B组,n=8)与第一部分相同。D组以骨化三醇溶液灌胃；E、F组分别以中、高浓度肾安颗粒灌胃；A、B、C组以等量生理盐水灌胃。灌胃容量1ml/100g/日,总疗程8周。用药前后检测各组大鼠血HGB、Scr、BUN、P3+、Ca2+、ALP、iPTH,取血前1天代谢笼收集24h尿,测Ucr并计算Ccr。
结果：各组大鼠存活情况：用药期间C组和D组各死亡1只,余各组大鼠均存活。用药前,C、D、E、F四组BUN、Scr、P3+与A、B两组比较明显升高,Ccr、Ca2+与A、B两组比较明显降低(P<0.05),ALP与A、B两组比较无明显变化(P>0.05)。用药8周后,A、B两组HGB、BUN、Scr、Ccr、P3+、Ca2+、ALP、iPTH与用药前比较无明显变化(P>0.05)；C组BUN、Scr、P3+、ALP、iPTH与用药前比较明显升高(P<0.05),Ca2+、Ccr、HGB与用药前比较明显降低；D组Ca2+与用药前比较明显升高(P<0.05),P3+较用药前略下降但无统计学意义(P>0..05),D组ALP与用药前比较降低(P<0.05),iPTH与用药前比较明显降低(P<0.01)；E组Ca 2+与用药前比较明显升高(P<0.05),P3+、ALP与用药前比较明显降低(P<0.05),iPTH与用药前比较显著下降(P<0.01)；F组Ca2+与用药前比较升高明显(P<0.05),P3+、ALP与用药前比较明显降低(P<0.05),iPTH与用药前比较显著降低(P<0.01)。用药后,D组Ca2+与C组比较明显升高(P<0.05),ALP、iPTH与C组比较均明显降低(P<0.05),P3+与C组比较无显著性差异(P>0.05)；E组Ca2+与C组比较明显升高(P<0.05),P3+、ALP、iPTH与C组比较均明显降低(P<0.05或P<0.01)；F组Ca2+与C组比较明显升高(P<0.05),P3+、ALP、iPTH与C组比较均显著降低(P<0.05或P<0.01)。用药8周后,E、F两组HGB、CCr与D组比较明显升高(P<0.05),Scr与D组比较明显降低(P<0.05),BUN与D组比较无显著性差异(P>0.05)。E、F两组Ca2+、ALP、iPTH与D组比较均无显著性差异(P>0.05),P3+与D组比较明显下降(P<0.05)；E、F两组间上述各指标比较无显著性差异(P>0.05)。
结论：肾安颗粒具有稳定残余肾模型大鼠肾功能、提高HGB、改善钙磷代谢、抑制甲状旁腺机能亢进的作用。
实验三KLOTHO基因在残余肾模型大鼠的表达及肾安颗粒的干预作用
目的：探讨KL基因在残余肾模型大鼠的表达及肾安颗粒的干预作用。
方法：分组方法及用药同第二部分。用药结束后,处死全部大鼠,取肾脏和股骨,肾组织常规包埋切片染色行光学显微镜检查,以双能X射线骨密度仪测定股骨头部的骨密度。采用Real-timePCR检测大鼠肾脏KLothomRNA的表达；采用Western blot检测肾脏KLotho蛋白、股骨FGF-23、BMP-7、OPG蛋白水平；免疫组化法检测股骨BMP-7、OPG表达；免疫荧光检测股骨FGF-23表达。
结果：骨密度：C组与A、B两组比较明显降低,E、F、D组与C组比较明显升高(P<0.05),E组与D组比较略有升高,但无统计学意义(P>0.05),F组与D组比较无显著性差异(P>0.05)。KLothomRNA:C组和D组的表达与A组和B组比较明显减低(P<0.01或P<0.05)；E、F组表达与C组比较明显增强(P<0.01)；E、F组两组表达与D组比较明显增强(P<0.05)。Klotho蛋白：A组的表达均高于其它各组,与C组相比明显增高(P<0.01)；E、F组的表达与C组和D组比较明显增高(P<0.05)；E组与F组间比较无差异性(P>0.05)。Western blot及免疫荧光检测FGF-23：C、D、F三组表达均明显高于A组和B组(P<0.05或P<0.01),E组表达与A组和B组比较无明显差异(P>0.05)；D、E、F三组表达明显低于C组(P<0.05)；E组表达低于D组和F组(P<0.05)。Western blot及免疫组化检测BMP-7：在大鼠股骨中,C、D、F三组表达明显低于A组和B组(P<0.05或P<0.01),E组表达略低于A组和B组但无统计学意义(P>0.05)；D、E、F三组表达与C组比较明显升高(P<0.05)；E、F两组表达高于D组(P<0.05)。Western blot及免疫组化检测OPG:C组表达明显低于A组和B组(P<0.05)；D、E、F三组表达明显高于C组(P<0.05)；D、E、F三组间比较无显著性差异(P>0.05)。KL表达与FGF-23、BMP-7、OPG表达的关系：在模型组,随着KLotho表达的下调,FGF-23表达升高,BMP-7、OPG表达降低；肾安干预后,随着KLotho表达的上调,FGF-23表达下降,BMP-7、OPG表达升高。
结论：KL基因在残余肾模型肾组织中的表达降低,与FGF-23呈明显负相关,与BMP-7、OPG呈明显正相关,肾安颗粒可能通过上调KL基因的表达,下调FGF-23,刺激成骨细胞BMP-7及OPG的合成,调节肾、骨、肠对钙、磷的转运,从而改善ROD。
Renal osteodystrophy(ROD) is the necessary complication of CKD (chronic kidney disease), which lowers the life quality and reduces survival time of patients. With the lower activity of kidney hydroxylase due to the destruction of structure and function of kidney, the production of 1,25 (0H)2 VitD3 is relatively or absolutely in sufficient, and synthesis and release of PTH is out of control, which is the core link of ROD. Klotho gene (KL) is related to senility, and expressed in brain choroids, Parathyroid gland and kidney, especially in renal cortical expression of distal tubule strongest. KL gene defect mice could exhibit senility phenotypic variation, which is similar with mankind syndrome of deficiency of kidney essence. It is approved that the expression of KL in kidney tissues decline dramatically in CKD, and the lower of KL could result in osteoporosis, which means KL may participate in producing ROD. In addition, bone morphogenic protein-1 (BMP-1), fibroblast growth factor-23 (FGF-23), and osteoprotegerin (OPG) are treated as bone hormones which are used to regulate calcium and phosphate metabolism in bone and gut and influence the generate process of ROD. Well, whether by virtue of protein regulation KL plays an important role in production of ROD? Once the hypothesis is approved, the pathogenesis of ROD could be further clarified and a new target would be provided for clinical treatment. In this paper, Rat 5/6 nephrectomy remnant kidney model is employed, regulation mechanisms of KL gene to BMP-1, FGF-23, and OPG are discussed, intervention of Shen'an Granular, such as compound-icariin、astragalin-1、rhubarb anthraquinone, is investigated. Anticipated results not only can deepen the understanding of the pathogenesis of ROD, but also can show the action mechanism of ROD prophylaxis and treatment with Chinese medicine to a certain extent.
Part I Making the rat model of remnant kidney
Objective To investigate a new kind of method of setting up animal model of remnant kidney and renal osteodstrophy.
Methods 48 Wistar rats were randomly divided into normal rats group(A group,n=8), pseudo- operation group(B group,n=8),model group(C group,n=32). After one week adaptive feeding, maked intraperitoneal injection of Sodium pentobarbital,the rats of C group were 2/3 left nephrectomized,which were feeding the high-phosphorus water next day, then right nephrectomized one week later. All of the rats were given normal diet, A group and B group drinking distilled water; Acquired the blood of rats eyeball a month after the 2/3 left nephrectomized,then examined HGB, Scr,BUN, P3+, Ca2+, ALP, iPTH, Collected the urinary of all of the 24hours before acquiring blood. Examined urine creatinine and calculated creatinine clearance rate.
Results Making model one month later, Both of A and B groups were lively, bright and tidy coat, weight gain; C group were apathetic, quiet and do not like to move, messy fur, body weight did not change significantly.Compared with A and B group, HGB of C group was decreased obviously (p<0.05);While, BUN and Scr, otherwise (p<0.01); Contrasted to A group, Ccr of C group was decreased dramatically (p<0.01); ALP of C group was increased dramatically (p<0.05); Compared with A group, iPTH of C group was increased obviously (p<0.01);While, Ca2+ otherwise(p<0.05); P3+ of C group was increased contrasted to A group (p<0.01). These Laboratory parameters was no significant difference between A and Bgroup(P>0.05).
Conclusions 5/6 nephrectomy combined with high phosphorus water one month can lead to disfunction of calcium and phosphorus metabolism of remnant kidney rats, then PTH increase, which demonstrates renal osteodstrophy arising.
PartⅡThe influences of calcium and phosphorus metabolism of rat model of remnant kidney and the interference effect of Shen'an Granular
Objective To probe the interference effect of Shen'an Granular in the calcium and phosphorus metabolism of rat model of remnant kidney.
Methods Wistar rats of model group above, were divided into 4 groups:model group (C group,n=8), calcitriol group (D group,n=8), moderate-dose Shen'an Granular group (E group,n=8);high-dose Shen'an Granular group(F group,n=8). A,B group same as part-1. D group feeding with calcitriol. E group feeding with moderate-dose Shen'an Granular.F group feeding with high-dose Shen'an Granular. A,B,C feeding with same dose normal saline. The total course of treatment was 8 weeks. Respectively examined HGB, Scr,BUN, P3+, Ca2+, ALP, iPTH of each group before and after medication, Collected the urinary of all of the 24hours before acquiring blood. Examined urine creatinine and calculated creatinine clearance rate.
Results Survival of the rats:each of C and D group had one died during the medication, the remaining were survival. Before medication,such as Scr, P3+ and BUN of C, D, E, F group were higher than A,B group, While Ca2+ and Ccr otherwise (p<0.05);After 8 weeks of medication, there was no significant difference between before and after treatment about the Laboratory parameters, which were HGB、BUN、Scr、Ccr、P3+、Ca2+、ALP and iPTH in A,B group (p>0.05); In D group, Ca2+ was increased after medication (p<0.05); While, P3+ and ALP otherwise (p<0.05);as well as iPTH(p<0.05); In E group, Ca2+ was increased after medication (p<0.05); While, P3+ and ALP otherwise (p<0.05);as well as iPTH(p<0.01);In F group, Ca2+ was increased after medication (p<0.05); While, P3+ and ALP otherwise (p<0.05);as well as iPTH(p<0.01); Compared with C group, Ca2+ of D group was increased obviously after medication (p<0.05);While, P3+ and ALP, iPTH, otherwise (p<0.05); Compared with C group, Ca2+ of E group was increased obviously (p<0.05);While, P3+ and ALP, iPTH, otherwise (p<0.05); Compared with C group, Ca2+ of Fgroup was increased obviously (p<0.05);While, P3+ and ALP, iPTH, otherwise (p<0.05); Compared with D group, the P3+, Ca2+, ALP, iPTH of E and F group (p<0.01) had no significant difference (P>0.05).After 8 weeks mediction, Compared with D group, HGB,Ccr of E,F group were to be better dramatically(p<0.05); While, Scr otherwise (p<0.05); as well as BUN, Ca2+, ALP, iPTH(P> 0.05);and P3+ decreased significantly(p<0.05); These Laboratory parameters were no significant difference between E and F group(P>0.05).
Conclusions Shen'an Granular can stabilize renal function, increase HGB,and also improve calcium and phosphorus metabolism of rat model of remnant kidney and inhibit hyper-parathyroidism.
PartⅢThe expression of Klotho gene in the rat model of remnant kidney and the interference effect of Shen'an Granular
Objective To probe the influences of the expression of Klotho gene in the rat model of remnant kidney and the interference effect of Shen'an Granular
Methods The drug and grouping method was same as part-2, After treatment, all rats were executed, then acquired renal and femoral bone, routine embedded sections of kidney stained line of optical microscopy, measured the density of the femoral head by dual energy X-ray. Examine the expression of Klotho mRNA of Wistar rats by RT-PCR,and Western blot was administered to measure the expression of kindey's Klotho and the thighbone'FGF-23,BMP-7,OPG, in the level of protein. Immunohistochemistry was used to detect the expression of thighbone' BMP-7 and OPG.Detected the expression of thighbone'FGF-23 by immunofluorescence.
Results Compared with C group, the expression of bone density in E,F,D group was to be better dramatically(p<0.05), E group was slightly higher than D group,but had no significant difference (P>0.05),as well as the comparison between F group and D group(P>0.05); Contrasted to A group and B group, KlothomRNA of C group and D group were obviously decreased (P<0.01 or P<0.05), KlothomRNA of E group and F group were obviously inecreased, compared with C group(P<0.01),as well as D group(p<0.05), the expression of Klotho protein of renal cortex,which was highest in A group (P<0.05),and significantly higher compared with C group (P<0.01), between E group and F groups showed no difference (P> 0.05). By Western blot and immunofluorescence detection of FGF23, the expression of FGF-23 in the E and F groups and D group were lower than C group (P< 0.05) otherwise of BMP-7 (P<0.05), the E and F group'BMP-7 was above D group in the level of protein (P<0.05). the expression of OPG in C group, was lower than the A group (P<0.05),while,each durg group was above it (P<0.05). between D and E,F group had no significant difference (P>0.05).
Conclusions The expression of Klotho gene in the rat model of renal osteodstrophy is suppressed, the low Klotho gene is closely related to FGF-23、BMP-7、OPG,Shen'an granular can produce favorable effects on the high-expression of Klotho gene and osteoblast factor, regulating calcium and phosphorus metabolism, improving renal osteodystrophy.
实验一大鼠残余肾模型的制备
目的：探讨大鼠残余肾并肾性骨病模型的制备方法。
方法：Wistar大鼠48只随机分为正常对照组(A组,n=8)、假手术组(B组,n=8)、造模组(C组,n=32)。经适应性喂养1周后,C组大鼠以戊巴比妥钠腹腔注射麻醉后,行2/3左肾切除,1周后再次行右肾切除。各组大鼠均予正常饮食,A组和B组饮蒸馏水,C组左肾切除术后第二天开始加磷酸二氢钠饮水。各组大鼠造模术后1月眼球取血,测定血红蛋白(HGB)、血肌酐(Scr)、尿素氮(BUN)、血磷(P3+)、血钙(Ca2+)、血清碱性磷酸酶(ALP)、血清全段甲状旁腺激素(iPTH)。取血前1天代谢笼收集24h尿,测尿肌酐(UCr)并计算内生肌酐清除率(Ccr)。
结果：造模术后1月,A、B两组大鼠活泼好动,毛色整齐光亮,体重增加；C组精神萎靡,安静不喜动,毛色杂乱,体重变化不明显。C组HGB与A组和B组比较明显降低(P<0.05)；C组BUN、Scr与A组和B组比较明显升高(P<0.01),C组Ccr与A组和B组比较明显降低(P<0.01)；C组ALP与A组和B组比较明显升高(P<0.05)；C组iPTH与A组和B组比较显著升高(P<0.01)；C组Ca2+与A组和B组比较明显降低(P<0.05)；C组P3+与A组和B组比较明显升高(P<0.01)。A、B两组间以上指标比较无显著性差异(P>0.05)。
结论：5/6肾切除加高磷饮水1月可以导致残余肾模型大鼠钙磷代谢异常,继发PTH升高,提示并发ROD。
实验二残余肾模型钙、磷代谢的变化及肾安颗粒的干预作用
目的：探讨残余肾模型大鼠钙、磷代谢的变化及肾安颗粒的干预作用。
方法：将第一部分实验中的造模组大鼠32只随机分为4组,即模型组(C组,n=8)、阳性药物骨化三醇对照组(D组,n=8)、肾安颗粒中剂量组(E组,n=8)、肾安颗粒高剂量组(F组,n=8)。正常对照组(A组,n=8)、假手术组(B组,n=8)与第一部分相同。D组以骨化三醇溶液灌胃；E、F组分别以中、高浓度肾安颗粒灌胃；A、B、C组以等量生理盐水灌胃。灌胃容量1ml/100g/日,总疗程8周。用药前后检测各组大鼠血HGB、Scr、BUN、P3+、Ca2+、ALP、iPTH,取血前1天代谢笼收集24h尿,测Ucr并计算Ccr。
结果：各组大鼠存活情况：用药期间C组和D组各死亡1只,余各组大鼠均存活。用药前,C、D、E、F四组BUN、Scr、P3+与A、B两组比较明显升高,Ccr、Ca2+与A、B两组比较明显降低(P<0.05),ALP与A、B两组比较无明显变化(P>0.05)。用药8周后,A、B两组HGB、BUN、Scr、Ccr、P3+、Ca2+、ALP、iPTH与用药前比较无明显变化(P>0.05)；C组BUN、Scr、P3+、ALP、iPTH与用药前比较明显升高(P<0.05),Ca2+、Ccr、HGB与用药前比较明显降低；D组Ca2+与用药前比较明显升高(P<0.05),P3+较用药前略下降但无统计学意义(P>0..05),D组ALP与用药前比较降低(P<0.05),iPTH与用药前比较明显降低(P<0.01)；E组Ca 2+与用药前比较明显升高(P<0.05),P3+、ALP与用药前比较明显降低(P<0.05),iPTH与用药前比较显著下降(P<0.01)；F组Ca2+与用药前比较升高明显(P<0.05),P3+、ALP与用药前比较明显降低(P<0.05),iPTH与用药前比较显著降低(P<0.01)。用药后,D组Ca2+与C组比较明显升高(P<0.05),ALP、iPTH与C组比较均明显降低(P<0.05),P3+与C组比较无显著性差异(P>0.05)；E组Ca2+与C组比较明显升高(P<0.05),P3+、ALP、iPTH与C组比较均明显降低(P<0.05或P<0.01)；F组Ca2+与C组比较明显升高(P<0.05),P3+、ALP、iPTH与C组比较均显著降低(P<0.05或P<0.01)。用药8周后,E、F两组HGB、CCr与D组比较明显升高(P<0.05),Scr与D组比较明显降低(P<0.05),BUN与D组比较无显著性差异(P>0.05)。E、F两组Ca2+、ALP、iPTH与D组比较均无显著性差异(P>0.05),P3+与D组比较明显下降(P<0.05)；E、F两组间上述各指标比较无显著性差异(P>0.05)。
结论：肾安颗粒具有稳定残余肾模型大鼠肾功能、提高HGB、改善钙磷代谢、抑制甲状旁腺机能亢进的作用。
实验三KLOTHO基因在残余肾模型大鼠的表达及肾安颗粒的干预作用
目的：探讨KL基因在残余肾模型大鼠的表达及肾安颗粒的干预作用。
方法：分组方法及用药同第二部分。用药结束后,处死全部大鼠,取肾脏和股骨,肾组织常规包埋切片染色行光学显微镜检查,以双能X射线骨密度仪测定股骨头部的骨密度。采用Real-timePCR检测大鼠肾脏KLothomRNA的表达；采用Western blot检测肾脏KLotho蛋白、股骨FGF-23、BMP-7、OPG蛋白水平；免疫组化法检测股骨BMP-7、OPG表达；免疫荧光检测股骨FGF-23表达。
结果：骨密度：C组与A、B两组比较明显降低,E、F、D组与C组比较明显升高(P<0.05),E组与D组比较略有升高,但无统计学意义(P>0.05),F组与D组比较无显著性差异(P>0.05)。KLothomRNA:C组和D组的表达与A组和B组比较明显减低(P<0.01或P<0.05)；E、F组表达与C组比较明显增强(P<0.01)；E、F组两组表达与D组比较明显增强(P<0.05)。Klotho蛋白：A组的表达均高于其它各组,与C组相比明显增高(P<0.01)；E、F组的表达与C组和D组比较明显增高(P<0.05)；E组与F组间比较无差异性(P>0.05)。Western blot及免疫荧光检测FGF-23：C、D、F三组表达均明显高于A组和B组(P<0.05或P<0.01),E组表达与A组和B组比较无明显差异(P>0.05)；D、E、F三组表达明显低于C组(P<0.05)；E组表达低于D组和F组(P<0.05)。Western blot及免疫组化检测BMP-7：在大鼠股骨中,C、D、F三组表达明显低于A组和B组(P<0.05或P<0.01),E组表达略低于A组和B组但无统计学意义(P>0.05)；D、E、F三组表达与C组比较明显升高(P<0.05)；E、F两组表达高于D组(P<0.05)。Western blot及免疫组化检测OPG:C组表达明显低于A组和B组(P<0.05)；D、E、F三组表达明显高于C组(P<0.05)；D、E、F三组间比较无显著性差异(P>0.05)。KL表达与FGF-23、BMP-7、OPG表达的关系：在模型组,随着KLotho表达的下调,FGF-23表达升高,BMP-7、OPG表达降低；肾安干预后,随着KLotho表达的上调,FGF-23表达下降,BMP-7、OPG表达升高。
结论：KL基因在残余肾模型肾组织中的表达降低,与FGF-23呈明显负相关,与BMP-7、OPG呈明显正相关,肾安颗粒可能通过上调KL基因的表达,下调FGF-23,刺激成骨细胞BMP-7及OPG的合成,调节肾、骨、肠对钙、磷的转运,从而改善ROD。
Renal osteodystrophy(ROD) is the necessary complication of CKD (chronic kidney disease), which lowers the life quality and reduces survival time of patients. With the lower activity of kidney hydroxylase due to the destruction of structure and function of kidney, the production of 1,25 (0H)2 VitD3 is relatively or absolutely in sufficient, and synthesis and release of PTH is out of control, which is the core link of ROD. Klotho gene (KL) is related to senility, and expressed in brain choroids, Parathyroid gland and kidney, especially in renal cortical expression of distal tubule strongest. KL gene defect mice could exhibit senility phenotypic variation, which is similar with mankind syndrome of deficiency of kidney essence. It is approved that the expression of KL in kidney tissues decline dramatically in CKD, and the lower of KL could result in osteoporosis, which means KL may participate in producing ROD. In addition, bone morphogenic protein-1 (BMP-1), fibroblast growth factor-23 (FGF-23), and osteoprotegerin (OPG) are treated as bone hormones which are used to regulate calcium and phosphate metabolism in bone and gut and influence the generate process of ROD. Well, whether by virtue of protein regulation KL plays an important role in production of ROD? Once the hypothesis is approved, the pathogenesis of ROD could be further clarified and a new target would be provided for clinical treatment. In this paper, Rat 5/6 nephrectomy remnant kidney model is employed, regulation mechanisms of KL gene to BMP-1, FGF-23, and OPG are discussed, intervention of Shen'an Granular, such as compound-icariin、astragalin-1、rhubarb anthraquinone, is investigated. Anticipated results not only can deepen the understanding of the pathogenesis of ROD, but also can show the action mechanism of ROD prophylaxis and treatment with Chinese medicine to a certain extent.
Part I Making the rat model of remnant kidney
Objective To investigate a new kind of method of setting up animal model of remnant kidney and renal osteodstrophy.
Methods 48 Wistar rats were randomly divided into normal rats group(A group,n=8), pseudo- operation group(B group,n=8),model group(C group,n=32). After one week adaptive feeding, maked intraperitoneal injection of Sodium pentobarbital,the rats of C group were 2/3 left nephrectomized,which were feeding the high-phosphorus water next day, then right nephrectomized one week later. All of the rats were given normal diet, A group and B group drinking distilled water; Acquired the blood of rats eyeball a month after the 2/3 left nephrectomized,then examined HGB, Scr,BUN, P3+, Ca2+, ALP, iPTH, Collected the urinary of all of the 24hours before acquiring blood. Examined urine creatinine and calculated creatinine clearance rate.
Results Making model one month later, Both of A and B groups were lively, bright and tidy coat, weight gain; C group were apathetic, quiet and do not like to move, messy fur, body weight did not change significantly.Compared with A and B group, HGB of C group was decreased obviously (p<0.05);While, BUN and Scr, otherwise (p<0.01); Contrasted to A group, Ccr of C group was decreased dramatically (p<0.01); ALP of C group was increased dramatically (p<0.05); Compared with A group, iPTH of C group was increased obviously (p<0.01);While, Ca2+ otherwise(p<0.05); P3+ of C group was increased contrasted to A group (p<0.01). These Laboratory parameters was no significant difference between A and Bgroup(P>0.05).
Conclusions 5/6 nephrectomy combined with high phosphorus water one month can lead to disfunction of calcium and phosphorus metabolism of remnant kidney rats, then PTH increase, which demonstrates renal osteodstrophy arising.
PartⅡThe influences of calcium and phosphorus metabolism of rat model of remnant kidney and the interference effect of Shen'an Granular
Objective To probe the interference effect of Shen'an Granular in the calcium and phosphorus metabolism of rat model of remnant kidney.
Methods Wistar rats of model group above, were divided into 4 groups:model group (C group,n=8), calcitriol group (D group,n=8), moderate-dose Shen'an Granular group (E group,n=8);high-dose Shen'an Granular group(F group,n=8). A,B group same as part-1. D group feeding with calcitriol. E group feeding with moderate-dose Shen'an Granular.F group feeding with high-dose Shen'an Granular. A,B,C feeding with same dose normal saline. The total course of treatment was 8 weeks. Respectively examined HGB, Scr,BUN, P3+, Ca2+, ALP, iPTH of each group before and after medication, Collected the urinary of all of the 24hours before acquiring blood. Examined urine creatinine and calculated creatinine clearance rate.
Results Survival of the rats:each of C and D group had one died during the medication, the remaining were survival. Before medication,such as Scr, P3+ and BUN of C, D, E, F group were higher than A,B group, While Ca2+ and Ccr otherwise (p<0.05);After 8 weeks of medication, there was no significant difference between before and after treatment about the Laboratory parameters, which were HGB、BUN、Scr、Ccr、P3+、Ca2+、ALP and iPTH in A,B group (p>0.05); In D group, Ca2+ was increased after medication (p<0.05); While, P3+ and ALP otherwise (p<0.05);as well as iPTH(p<0.05); In E group, Ca2+ was increased after medication (p<0.05); While, P3+ and ALP otherwise (p<0.05);as well as iPTH(p<0.01);In F group, Ca2+ was increased after medication (p<0.05); While, P3+ and ALP otherwise (p<0.05);as well as iPTH(p<0.01); Compared with C group, Ca2+ of D group was increased obviously after medication (p<0.05);While, P3+ and ALP, iPTH, otherwise (p<0.05); Compared with C group, Ca2+ of E group was increased obviously (p<0.05);While, P3+ and ALP, iPTH, otherwise (p<0.05); Compared with C group, Ca2+ of Fgroup was increased obviously (p<0.05);While, P3+ and ALP, iPTH, otherwise (p<0.05); Compared with D group, the P3+, Ca2+, ALP, iPTH of E and F group (p<0.01) had no significant difference (P>0.05).After 8 weeks mediction, Compared with D group, HGB,Ccr of E,F group were to be better dramatically(p<0.05); While, Scr otherwise (p<0.05); as well as BUN, Ca2+, ALP, iPTH(P> 0.05);and P3+ decreased significantly(p<0.05); These Laboratory parameters were no significant difference between E and F group(P>0.05).
Conclusions Shen'an Granular can stabilize renal function, increase HGB,and also improve calcium and phosphorus metabolism of rat model of remnant kidney and inhibit hyper-parathyroidism.
PartⅢThe expression of Klotho gene in the rat model of remnant kidney and the interference effect of Shen'an Granular
Objective To probe the influences of the expression of Klotho gene in the rat model of remnant kidney and the interference effect of Shen'an Granular
Methods The drug and grouping method was same as part-2, After treatment, all rats were executed, then acquired renal and femoral bone, routine embedded sections of kidney stained line of optical microscopy, measured the density of the femoral head by dual energy X-ray. Examine the expression of Klotho mRNA of Wistar rats by RT-PCR,and Western blot was administered to measure the expression of kindey's Klotho and the thighbone'FGF-23,BMP-7,OPG, in the level of protein. Immunohistochemistry was used to detect the expression of thighbone' BMP-7 and OPG.Detected the expression of thighbone'FGF-23 by immunofluorescence.
Results Compared with C group, the expression of bone density in E,F,D group was to be better dramatically(p<0.05), E group was slightly higher than D group,but had no significant difference (P>0.05),as well as the comparison between F group and D group(P>0.05); Contrasted to A group and B group, KlothomRNA of C group and D group were obviously decreased (P<0.01 or P<0.05), KlothomRNA of E group and F group were obviously inecreased, compared with C group(P<0.01),as well as D group(p<0.05), the expression of Klotho protein of renal cortex,which was highest in A group (P<0.05),and significantly higher compared with C group (P<0.01), between E group and F groups showed no difference (P> 0.05). By Western blot and immunofluorescence detection of FGF23, the expression of FGF-23 in the E and F groups and D group were lower than C group (P< 0.05) otherwise of BMP-7 (P<0.05), the E and F group'BMP-7 was above D group in the level of protein (P<0.05). the expression of OPG in C group, was lower than the A group (P<0.05),while,each durg group was above it (P<0.05). between D and E,F group had no significant difference (P>0.05).
Conclusions The expression of Klotho gene in the rat model of renal osteodstrophy is suppressed, the low Klotho gene is closely related to FGF-23、BMP-7、OPG,Shen'an granular can produce favorable effects on the high-expression of Klotho gene and osteoblast factor, regulating calcium and phosphorus metabolism, improving renal osteodystrophy.
引文
[1]Legg VA. Close look at renal osteodystrophy nutritional disturbances, and inflammation. Am J Nurs;2005,105(6):40-49.
[2]Sharon M,Moea TB,Driiekeb.Management of Secondary Hyperparathyroidism. The Importance and the Challenge of Controlling Parathyroid Hormone Levels with without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product. American Journa of Nephrology,2003,23:369-379.
[3]Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun.1998.242(3):626-630.
[4]Cavanagh EM, Inserra F, Ferder L. Angiotensin Ⅱ blockade:a strategy to slow ageing by protecting mitochondria. Cardiovasc Res.2011. 89(1):31-40.)
[5]Zhou Z, Hu CP, Wang CJ, Li TT, Peng J, Li YJ. Calcitonin gene-related peptide inhibits angiotensin II-induced endothelial progenitor cells senescence through up-regulation of klotho expression. Atherosclerosis.2010.213(1):92-101.
[6]王小琴,谭大琦,金劲松.肾安颗粒治疗慢性肾衰竭的临床研究.中国中西医结合肾病杂志.2003.(07)：393-395.
[7]胡安康,朱孝荣,袁红花.慢性肾衰竭大鼠模型的建立.中国实验动物学报,2011,19(1)：34-38.
[8]杨鹏,张三印,李明权.慢性肾功能衰竭大鼠模型的比较研究.云南中医中药杂志,2010,12(4)：38-41.
[9]AquilesJARA,Jordi BOVER,ArnoldJ. FELSENFELD.Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney International,1995,47:1746-1751.
[10]周家俊,关鑫,赵东.部分肾切除加高磷饮食所致大鼠肾性骨病模型研究.中国中西医结合肾病杂志,2002,3(10)：567-569.
[11]张学红,杜海峰,刘海丽.自拟补肾骨宁汤对肾性骨病大鼠肾功能影响的实验研究.山西医药杂志,2008,37(8)：684-686.
[12]唐荣,唐得檾.慢性肾脏病患者骨矿物质紊乱的发生机制与治疗的研究进展.广东医学院学报,2010,28(2)：202-204.
[13]Levin A Bakris G L, Molitch M, et al.Prevalence Serum vitamin D, PTH,calcium,and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disese [J] Kidney Int,2007,71(1):30-38.
[14]Martin KJ,Olgaard K. Diagnosis, Assessment, and Treatment of Bone Turnover Abnormalities in Renal Osteodystrophy.Am J Kidney Dis,2004,43(3):558-565.
[15]El- Kishawi AM, El- NahasAM. Renal Osteodystrophy:Review of the Disease and its Treatment. Saudi J Kidney Dis Transpl,2006,17(3):373-382.
[16]Zheng Falei, Yuan Qunsheng. Diagnosis and treatment of renal osteodystrophy and the progress of the new problem. Practical Clinical Journal of Hospital,2006,3(4):25(in Chinese).
[17]Slatopolsky E.The intact nephron hypothesis:the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl.2011 Apr;(121):S3-8.
[18]Block GA,Klassen PS,Lazarus JM,et al.Mineral metabolism,mortality,and mobidity in maintenance hemodialysis.J Am Soc Nephrol,2004,15:2208-2218.
[19]Block GA,Port FK.Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis,2000,35:1226-1237.
[20]Maria Paz Marco,Lourdes Sraver,Angels Betriu,et al.Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population.Kidney Int.2003,63(Supp185):S111-114.
[21]Slatopolsky E, Gonzalez E, Martin K.Pathogenesis and treatment of renal osteodystrophy. Blood Purif.2003;21(4-5):318-326.
[22]Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis.2003 May;41(5):997-1007.
[23]Young E, Satayathum S, Pisoni R, et al. new draft NKF-K/DOQI and europeanbestpractice guidelines in countries of the dialy—sis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant.2003,18(suppl4):677-687.
[24]Cannata-Andia JB, Rodriguez-Garcia M, Romαn-Garcia P,New therapies:calcimimetics, phosphate binders and vitamin D receptor activators.PediatrNephrol.2010 Apr;25(4):609-16. Epub 2010 Feb 12.
[25]Cases A. Recent advances in nephrology. Drug News Perspect Drug News Perspect,2003,16:471-477.
[26]Kanawa I,Yamaguchi T,Yamamoto M, Yamauchi M, Kurioka S, Yanos, Sugimoto T:Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diatebes mellitus. J Clin Endocrinol Metab,2009,94:45-49.
[27]Tan X, Wen X, Liu Y. Paricalcitriol inhibits renal Inflammation by Promoting Vitamin D Receptor-Mediated Sequestration of NF-κB Signaling. J Am Soc Nephrol,2008,19:1741-1752.
[28]El-Kishawi AM, El-Nahas AM. Renal Osteodystrophy:Reviewof the Disease and its Treatment. Saudi J Kidney Dis Transpl.2006,17(3):373-382.
[29]Zheng Falei, Yuan Qunsheng. Diagnosis and treatment of renal osteodystrophy and the progress of the new problem. Practical Clinical Journal of Hospital.2006,3(4):25(in Chinese).
[30]王小琴.肾安提取液对3T3细胞增殖及α-肌动蛋白表达影响的实验研究.中医药导报,2006,12(10)：10-12.
[31]吴涛,徐俊昌,南开辉,等.淫羊藿苷促进羊骨髓间充质干细胞的增殖和成骨分化[J].中国组织工程研究与临床康复,2009,13(19)：3725-3729.
[32]翟文生,王文英,刘华等.黄芪、大黄、雷公藤多苷对大鼠MsC增生及表达TGF-β1的影响.河南中医,2011,31(3)：237-239.
[33]郭啸华,刘志红,戴春笋等.大黄酸抑制TGF-β1诱导的肾小管上皮细胞肥大及细胞外基质产生[J].肾脏病与透析肾移植杂志,2001,10(2)：101-105.。
[34]Anamizu Y, Kawaguchi H, Seichi A et al. KLotho insufficiency causes decrease of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal anterior horn cells. Acta Neuropathol(Berl) 2005,109:457-466.
[35]Kuro-o M. Klot ho in chronic kidney disease--what's new?Nephrol Dial Transplant,2009,24 (6):1705-1708.
[36]Marrya H, Inomata M, Fujimori T et al. Klotho protein deficiency leads to overactive-ation of mu-calpain. J Biol Chen,2002, 277(38):35503-35508.
[37]Nabeshima Y. Klotho:a fundamental regulator of aging. Agening Res Rev,2002,1(4):627-638.
[38]Tsujikawa H,Kurotaki Y,Fujimori T et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory crcuit of vitamin D endocrine system. Mol Endocrinol,2003,17(12):2393-2403.
[39]唐荣,周巧玲,彭卫生等.血管紧张素Ⅱ对肾小管上皮细胞klotho基因表达的影响.肾脏病与透析肾移植杂志,2008,17(3)：242-247.
[40]顾怡然,章蓉,竺淑佳等.Klotho基因在骨质疏松大鼠模型中的表达.复旦学报(自然科学版),2007,46(6)：874-877.
[41]Kuro-O M. Phosphate and Klotho. Kidney Int Suppl.2011 Apr;(121):S20-3.
[42]KamemoriM, Ohyama Y, KurabayashiMet al. Expression of KLotho protein in the inner ear. Hear Res 2002,171:103-110.
[43]Chang Q,Hoefs S,van der Kemp AW,et al.The beta- glucuronidase KLotho hydrolyzes and activates the TRPV5 channel.Science,2005,310(5747):490-493.
[44]LiSA,Watanabe M,Yamada H,et al.Immunohistochemical localization of KLotho protein in brain,kidney,and reproductive organs of mice.Cell Struct Funct,2004,29(4):91-99.
[45]Miyamoto K, Ito M, Segawa H, et al. Molecular targets of hyperphosphataemia in chronic renal failure. Nephrol Dial Transplant.2003 Jun;18Suppl 3:iii79-80.
[46]Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol.2007 Nov;293(5):F1577-83. Epub 2007 Aug 15.
[47]Ramon I, Kleynen P, Body JJ, et al. Fibroblast growth factor 23 and its role phosphate homeostasis. Eur J Endocrinol,2010,162(1):1-10.
[48]Yokota H,Raposo JF, Chen A, et al. Evaluation of the Role of FGF23 in Mineral Metabolism. Gene Rene Regul Syst Bio,2009,3:131-142
[49]John GB, Cheng CY, Kuro-O M.Role of Klotho in Aging, Phosphate Metabolism, and CKD.Am J Kidney Dis.2011 Apr 14.
[50]Nitta K.Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease.Int J Nephrol.2010 Dec 30;2010:167984.
[51]Kurosu H,Ogawa Y,Miyoshi M,et al.Regulation of fibroblast growth factor-23 signaling by KLotho.J Biol Chem,2006,281(10):6120-6123.
[52]Silver J, Naveh-Many T.FGF23 and the parathyroid glands.Pediatr Nephrol.2010 Nov;25(11):2241-5.
[53]Kuro-O M.Phosphate and Klotho.Kidney Int Suppl.2011 Apr;(121):S20-3.
[54]Ketteler M,Biggar PH. As nature did not predict dialysis-what we can learn from FGF23 in end-stage renal disease? Nephrol Dial Transplant,2009,24 (9):2618-2620.
[55]Min H,Morony S,Sarosi I,et al. osteoprogerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis J Exp Med,2000,192(4):463-474.
[56]田庆显,黄公怡.1,25二羟维生素D3对小鼠成骨细胞OPG和RNAKL基因表达的影响.中国医学科学院学报,2004,26(4)：418-422.
[57]刘亦恒,臧洪敏,张海英等.淫羊藿总黄酮对成骨细胞中OPG和RANKL mRNA基因表达影响的实验研究.中药材,2005,28(12)：1076-1078.
[58]周乐,吴燎,崔铁.淫羊藿对肾阳虚雄性大鼠肾脏和股骨BMP-7表达的影响.中国骨质疏松杂志,2008,14(2)：90-94.
[59]王小琴,邵朝弟,金劲松等.肾安提取液对5/6肾切除模型肾组织学的影响.临床肾脏病杂志,2004,4(2)：76-79
[60]王小琴,邵朝弟,金劲松等.肾安提取液对5/6肾切除大鼠肾功能的影响.临床肾脏病杂志,2006,6(4)：179-181.
[61]王小琴,邵朝弟,金劲松.肾安提取液对大鼠残余肾的病理学影响.中国中西医结合肾病杂志,2007,8(12)：716-717,I0009.
[62]王小琴,谭大琦,李卫星等.复方黄芪甲苷、淫羊霍苷、大黄葸醌提取物对残余肾模型PCNA表达及肾功能的影响.临床医药杂志,2005,18(2)：1-13.
[63]王小琴,向少伟,唐庆.肾安提取液对糖尿病小鼠肾脏AP-1和TGF-β1表达的影响.中国中西医结合肾病杂志,2010,11(12)：1057-1061.
[64]Westerberg PA, Linder T, Wikstrom B, et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant,2007,22(11)3202-3207.
[1]Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature.1997. 390(6655):45-51.
[2]Nagai T, Yamada K, Kim HC, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice:a role of oxidative stress. FASEB J.2003.17(1):50-52.
[3]Kamemori M, Ohyama Y, Kurabayashi M, Takahashi K, Nagai R, Furuya N. Expression of Klotho protein in the inner ear. Hear Res. 2002.171(1-2):103-110.
[4]Anamizu Y, Kawaguchi H, Seichi A, et al. Klotho insufficiency causes decrease of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal anterior horn cells. Acta Neuropathol.2005.109(5):457-466.
[5]Torres PU, Prie D, Molina-Bletry V, et al. Klotho:an antiaging protein involved in mineral and vitamin D metabolism.Kidney Int. 2007 Apr;71(8):730-7. Epub 2007 Feb 28.
[6]Kuro-o M. Klotho in chronic kidney disease--what's new?Nephrol Dial Transplant,2009,24 (6):1705-1708.
[7]Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science (80-).2005.309(5742): 1829-1833.
[8]Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J.2009.23(2):433-441.
[9]Kurosu H, Kuro-O M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol.2009. 299(1):72-78.
[10]Kato Y, Arakawa E, Kinoshita S, et al. Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys. Biochem Biophys Res Commun.2000.267(2): 597-602.
[11]Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med. 2004.43(1):9-17.
[12]Cheng X, Zhou Q, Lin S, Wu R. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban.2010.35(10):1048-1056.
[13]Mukai Y, Shimokawa H, Higashi M, et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol.2002. 22(9):1445-1450.
[14]Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension.2009. 54(4):810-817.
[15]周巧玲,林书典,彭卫生等.缬沙坦对血管紧张素Ⅱ抑制klotho基因表达的影响.肾脏病与透析肾移植杂志.2007.16(4)：336-339.
[16]唐荣,周巧玲,舒金勇等.冬虫夏草提取液对肾小管上皮细胞Klotho表达和凋亡的影响.中南大学学报(医学版).2009.34(4)：300-307.
[17]Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology.2002.143(2):683-689.
[18]Zhou XJ, Saxena R, Liu Z, Vaziri ND, Silva FG. Renal senescence in 2008:progress and challenges. Int Urol Nephrol.2008.40(3): 823-839.
[19]Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev. 2009.8(1):43-51.
[20]Alexander RT, Woudenberg-Vrenken TE, Buurman J, et al. Klotho prevents renal calcium loss. J Am Soc Nephrol.2009.20(11): 2371-2379.
[21]Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev.2005.85(1):373-422.
[22]Chang Q, Hoefs S, der Kemp AW v, Topala CN, Bindels RJ, Hoenderop JG The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science (80-).2005.310(5747): 490-493.
[23]Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A.2008.105(28):9805-9810.
[24]Schiavi SC, Kumar R. The phosphatonin pathway:new insights in phosphate homeostasis. Kidney Int.2004.65(1):1-14.
[25]Liu S, Vierthaler L, Tang W, et al FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol.2008 Dec;19(12):2342-50. Epub 2008 Aug 27.
[26]Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A.2010.107(1):407-412.
[27]Hofman-Bang J, Martuseviciene G, Santini MA, et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int.2010 Dec;78(11):1119-27.
[28]Nabeshima Y. Discovery of alpha-Klotho unveiled new insights into calcium and phosphate homeostasis. Proc Jpn Acad Ser B Phys Biol Sci.2009.85(3):125-141.
[29]Mendoza-Nunez VM, Ruiz-Ramos M, Sanchez-Rodriguez MA, Retana-Ugalde R, Munoz-Sanchez JL. Aging-related oxidative stress in healthy humans. Tohoku J Exp Med.2007.213(3): 261-268.
[30]Rakugi H, Matsukawa N, Ishikawa K, et al. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine.2007.31(1):82-87.
[31]姜靖,黄岚,赵晓辉等.Klotho对老龄小鼠内皮祖细胞修复损伤血管内膜的影响.中国药业.2009.18(24)：22-24.
[32]Zhou Z, Hu CP, Wang CJ, et al. Calcitonin gene-related peptide inhibits angiotensin II-induced endothelial progenitor cells senescence through up-regulation of klotho expression.Atherosclerosis.2010 Nov;213(1):92-101.
[33]Zhang H, Li Y, Fan Y, et al. Klotho is a target gene of PPAR-gamma.Kidney Int.2008 Sep;74(6):732-9. Epub 2008 Jun 11.
[34]Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun.2001.280(4):1015-1020.
[35]Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol.2009.20(2): 388-396.
[36]Haruna Y, Kashihara N, Satoh M, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A.2007.104(7):2331-236.
[37]Sugiura H, Yoshida T, Tsuchiya K, et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant.2005.20(12):2636-2645.
[38]Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med.2008.359(6):584-592.
[39]Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol.2008.102(1):47-53.
[40]Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med.2004.351(13):1296-1305.
[41]Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation.2003. 108(17):2154-2169.
[42]Tsujikawa H, Kurotaki Y, Fujimori T, et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol.2003; 17:2393-2403.
[43]Doi S, Zou Y, Togao O, et al. Klotho inhibits transforming growth factor-betal (TGF-betal) signaling and suppresses renal fibrosis and cancer metastasis in mice.J Biol Chem.2011 Mar 11;286(10):8655-65.
[44]Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm.2009.2009:137072.
[45]Hu MC, Shi M, Zhang J, et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int.2010.78(12):1240-1251.
[2]Sharon M,Moea TB,Driiekeb.Management of Secondary Hyperparathyroidism. The Importance and the Challenge of Controlling Parathyroid Hormone Levels with without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product. American Journa of Nephrology,2003,23:369-379.
[3]Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun.1998.242(3):626-630.
[4]Cavanagh EM, Inserra F, Ferder L. Angiotensin Ⅱ blockade:a strategy to slow ageing by protecting mitochondria. Cardiovasc Res.2011. 89(1):31-40.)
[5]Zhou Z, Hu CP, Wang CJ, Li TT, Peng J, Li YJ. Calcitonin gene-related peptide inhibits angiotensin II-induced endothelial progenitor cells senescence through up-regulation of klotho expression. Atherosclerosis.2010.213(1):92-101.
[6]王小琴,谭大琦,金劲松.肾安颗粒治疗慢性肾衰竭的临床研究.中国中西医结合肾病杂志.2003.(07)：393-395.
[7]胡安康,朱孝荣,袁红花.慢性肾衰竭大鼠模型的建立.中国实验动物学报,2011,19(1)：34-38.
[8]杨鹏,张三印,李明权.慢性肾功能衰竭大鼠模型的比较研究.云南中医中药杂志,2010,12(4)：38-41.
[9]AquilesJARA,Jordi BOVER,ArnoldJ. FELSENFELD.Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney International,1995,47:1746-1751.
[10]周家俊,关鑫,赵东.部分肾切除加高磷饮食所致大鼠肾性骨病模型研究.中国中西医结合肾病杂志,2002,3(10)：567-569.
[11]张学红,杜海峰,刘海丽.自拟补肾骨宁汤对肾性骨病大鼠肾功能影响的实验研究.山西医药杂志,2008,37(8)：684-686.
[12]唐荣,唐得檾.慢性肾脏病患者骨矿物质紊乱的发生机制与治疗的研究进展.广东医学院学报,2010,28(2)：202-204.
[13]Levin A Bakris G L, Molitch M, et al.Prevalence Serum vitamin D, PTH,calcium,and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disese [J] Kidney Int,2007,71(1):30-38.
[14]Martin KJ,Olgaard K. Diagnosis, Assessment, and Treatment of Bone Turnover Abnormalities in Renal Osteodystrophy.Am J Kidney Dis,2004,43(3):558-565.
[15]El- Kishawi AM, El- NahasAM. Renal Osteodystrophy:Review of the Disease and its Treatment. Saudi J Kidney Dis Transpl,2006,17(3):373-382.
[16]Zheng Falei, Yuan Qunsheng. Diagnosis and treatment of renal osteodystrophy and the progress of the new problem. Practical Clinical Journal of Hospital,2006,3(4):25(in Chinese).
[17]Slatopolsky E.The intact nephron hypothesis:the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl.2011 Apr;(121):S3-8.
[18]Block GA,Klassen PS,Lazarus JM,et al.Mineral metabolism,mortality,and mobidity in maintenance hemodialysis.J Am Soc Nephrol,2004,15:2208-2218.
[19]Block GA,Port FK.Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis,2000,35:1226-1237.
[20]Maria Paz Marco,Lourdes Sraver,Angels Betriu,et al.Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population.Kidney Int.2003,63(Supp185):S111-114.
[21]Slatopolsky E, Gonzalez E, Martin K.Pathogenesis and treatment of renal osteodystrophy. Blood Purif.2003;21(4-5):318-326.
[22]Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis.2003 May;41(5):997-1007.
[23]Young E, Satayathum S, Pisoni R, et al. new draft NKF-K/DOQI and europeanbestpractice guidelines in countries of the dialy—sis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant.2003,18(suppl4):677-687.
[24]Cannata-Andia JB, Rodriguez-Garcia M, Romαn-Garcia P,New therapies:calcimimetics, phosphate binders and vitamin D receptor activators.PediatrNephrol.2010 Apr;25(4):609-16. Epub 2010 Feb 12.
[25]Cases A. Recent advances in nephrology. Drug News Perspect Drug News Perspect,2003,16:471-477.
[26]Kanawa I,Yamaguchi T,Yamamoto M, Yamauchi M, Kurioka S, Yanos, Sugimoto T:Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diatebes mellitus. J Clin Endocrinol Metab,2009,94:45-49.
[27]Tan X, Wen X, Liu Y. Paricalcitriol inhibits renal Inflammation by Promoting Vitamin D Receptor-Mediated Sequestration of NF-κB Signaling. J Am Soc Nephrol,2008,19:1741-1752.
[28]El-Kishawi AM, El-Nahas AM. Renal Osteodystrophy:Reviewof the Disease and its Treatment. Saudi J Kidney Dis Transpl.2006,17(3):373-382.
[29]Zheng Falei, Yuan Qunsheng. Diagnosis and treatment of renal osteodystrophy and the progress of the new problem. Practical Clinical Journal of Hospital.2006,3(4):25(in Chinese).
[30]王小琴.肾安提取液对3T3细胞增殖及α-肌动蛋白表达影响的实验研究.中医药导报,2006,12(10)：10-12.
[31]吴涛,徐俊昌,南开辉,等.淫羊藿苷促进羊骨髓间充质干细胞的增殖和成骨分化[J].中国组织工程研究与临床康复,2009,13(19)：3725-3729.
[32]翟文生,王文英,刘华等.黄芪、大黄、雷公藤多苷对大鼠MsC增生及表达TGF-β1的影响.河南中医,2011,31(3)：237-239.
[33]郭啸华,刘志红,戴春笋等.大黄酸抑制TGF-β1诱导的肾小管上皮细胞肥大及细胞外基质产生[J].肾脏病与透析肾移植杂志,2001,10(2)：101-105.。
[34]Anamizu Y, Kawaguchi H, Seichi A et al. KLotho insufficiency causes decrease of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal anterior horn cells. Acta Neuropathol(Berl) 2005,109:457-466.
[35]Kuro-o M. Klot ho in chronic kidney disease--what's new?Nephrol Dial Transplant,2009,24 (6):1705-1708.
[36]Marrya H, Inomata M, Fujimori T et al. Klotho protein deficiency leads to overactive-ation of mu-calpain. J Biol Chen,2002, 277(38):35503-35508.
[37]Nabeshima Y. Klotho:a fundamental regulator of aging. Agening Res Rev,2002,1(4):627-638.
[38]Tsujikawa H,Kurotaki Y,Fujimori T et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory crcuit of vitamin D endocrine system. Mol Endocrinol,2003,17(12):2393-2403.
[39]唐荣,周巧玲,彭卫生等.血管紧张素Ⅱ对肾小管上皮细胞klotho基因表达的影响.肾脏病与透析肾移植杂志,2008,17(3)：242-247.
[40]顾怡然,章蓉,竺淑佳等.Klotho基因在骨质疏松大鼠模型中的表达.复旦学报(自然科学版),2007,46(6)：874-877.
[41]Kuro-O M. Phosphate and Klotho. Kidney Int Suppl.2011 Apr;(121):S20-3.
[42]KamemoriM, Ohyama Y, KurabayashiMet al. Expression of KLotho protein in the inner ear. Hear Res 2002,171:103-110.
[43]Chang Q,Hoefs S,van der Kemp AW,et al.The beta- glucuronidase KLotho hydrolyzes and activates the TRPV5 channel.Science,2005,310(5747):490-493.
[44]LiSA,Watanabe M,Yamada H,et al.Immunohistochemical localization of KLotho protein in brain,kidney,and reproductive organs of mice.Cell Struct Funct,2004,29(4):91-99.
[45]Miyamoto K, Ito M, Segawa H, et al. Molecular targets of hyperphosphataemia in chronic renal failure. Nephrol Dial Transplant.2003 Jun;18Suppl 3:iii79-80.
[46]Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol.2007 Nov;293(5):F1577-83. Epub 2007 Aug 15.
[47]Ramon I, Kleynen P, Body JJ, et al. Fibroblast growth factor 23 and its role phosphate homeostasis. Eur J Endocrinol,2010,162(1):1-10.
[48]Yokota H,Raposo JF, Chen A, et al. Evaluation of the Role of FGF23 in Mineral Metabolism. Gene Rene Regul Syst Bio,2009,3:131-142
[49]John GB, Cheng CY, Kuro-O M.Role of Klotho in Aging, Phosphate Metabolism, and CKD.Am J Kidney Dis.2011 Apr 14.
[50]Nitta K.Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease.Int J Nephrol.2010 Dec 30;2010:167984.
[51]Kurosu H,Ogawa Y,Miyoshi M,et al.Regulation of fibroblast growth factor-23 signaling by KLotho.J Biol Chem,2006,281(10):6120-6123.
[52]Silver J, Naveh-Many T.FGF23 and the parathyroid glands.Pediatr Nephrol.2010 Nov;25(11):2241-5.
[53]Kuro-O M.Phosphate and Klotho.Kidney Int Suppl.2011 Apr;(121):S20-3.
[54]Ketteler M,Biggar PH. As nature did not predict dialysis-what we can learn from FGF23 in end-stage renal disease? Nephrol Dial Transplant,2009,24 (9):2618-2620.
[55]Min H,Morony S,Sarosi I,et al. osteoprogerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis J Exp Med,2000,192(4):463-474.
[56]田庆显,黄公怡.1,25二羟维生素D3对小鼠成骨细胞OPG和RNAKL基因表达的影响.中国医学科学院学报,2004,26(4)：418-422.
[57]刘亦恒,臧洪敏,张海英等.淫羊藿总黄酮对成骨细胞中OPG和RANKL mRNA基因表达影响的实验研究.中药材,2005,28(12)：1076-1078.
[58]周乐,吴燎,崔铁.淫羊藿对肾阳虚雄性大鼠肾脏和股骨BMP-7表达的影响.中国骨质疏松杂志,2008,14(2)：90-94.
[59]王小琴,邵朝弟,金劲松等.肾安提取液对5/6肾切除模型肾组织学的影响.临床肾脏病杂志,2004,4(2)：76-79
[60]王小琴,邵朝弟,金劲松等.肾安提取液对5/6肾切除大鼠肾功能的影响.临床肾脏病杂志,2006,6(4)：179-181.
[61]王小琴,邵朝弟,金劲松.肾安提取液对大鼠残余肾的病理学影响.中国中西医结合肾病杂志,2007,8(12)：716-717,I0009.
[62]王小琴,谭大琦,李卫星等.复方黄芪甲苷、淫羊霍苷、大黄葸醌提取物对残余肾模型PCNA表达及肾功能的影响.临床医药杂志,2005,18(2)：1-13.
[63]王小琴,向少伟,唐庆.肾安提取液对糖尿病小鼠肾脏AP-1和TGF-β1表达的影响.中国中西医结合肾病杂志,2010,11(12)：1057-1061.
[64]Westerberg PA, Linder T, Wikstrom B, et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant,2007,22(11)3202-3207.
[1]Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature.1997. 390(6655):45-51.
[2]Nagai T, Yamada K, Kim HC, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice:a role of oxidative stress. FASEB J.2003.17(1):50-52.
[3]Kamemori M, Ohyama Y, Kurabayashi M, Takahashi K, Nagai R, Furuya N. Expression of Klotho protein in the inner ear. Hear Res. 2002.171(1-2):103-110.
[4]Anamizu Y, Kawaguchi H, Seichi A, et al. Klotho insufficiency causes decrease of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal anterior horn cells. Acta Neuropathol.2005.109(5):457-466.
[5]Torres PU, Prie D, Molina-Bletry V, et al. Klotho:an antiaging protein involved in mineral and vitamin D metabolism.Kidney Int. 2007 Apr;71(8):730-7. Epub 2007 Feb 28.
[6]Kuro-o M. Klotho in chronic kidney disease--what's new?Nephrol Dial Transplant,2009,24 (6):1705-1708.
[7]Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science (80-).2005.309(5742): 1829-1833.
[8]Nakatani T, Sarraj B, Ohnishi M, et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J.2009.23(2):433-441.
[9]Kurosu H, Kuro-O M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol.2009. 299(1):72-78.
[10]Kato Y, Arakawa E, Kinoshita S, et al. Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys. Biochem Biophys Res Commun.2000.267(2): 597-602.
[11]Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med. 2004.43(1):9-17.
[12]Cheng X, Zhou Q, Lin S, Wu R. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban.2010.35(10):1048-1056.
[13]Mukai Y, Shimokawa H, Higashi M, et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol.2002. 22(9):1445-1450.
[14]Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension.2009. 54(4):810-817.
[15]周巧玲,林书典,彭卫生等.缬沙坦对血管紧张素Ⅱ抑制klotho基因表达的影响.肾脏病与透析肾移植杂志.2007.16(4)：336-339.
[16]唐荣,周巧玲,舒金勇等.冬虫夏草提取液对肾小管上皮细胞Klotho表达和凋亡的影响.中南大学学报(医学版).2009.34(4)：300-307.
[17]Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology.2002.143(2):683-689.
[18]Zhou XJ, Saxena R, Liu Z, Vaziri ND, Silva FG. Renal senescence in 2008:progress and challenges. Int Urol Nephrol.2008.40(3): 823-839.
[19]Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev. 2009.8(1):43-51.
[20]Alexander RT, Woudenberg-Vrenken TE, Buurman J, et al. Klotho prevents renal calcium loss. J Am Soc Nephrol.2009.20(11): 2371-2379.
[21]Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev.2005.85(1):373-422.
[22]Chang Q, Hoefs S, der Kemp AW v, Topala CN, Bindels RJ, Hoenderop JG The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science (80-).2005.310(5747): 490-493.
[23]Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A.2008.105(28):9805-9810.
[24]Schiavi SC, Kumar R. The phosphatonin pathway:new insights in phosphate homeostasis. Kidney Int.2004.65(1):1-14.
[25]Liu S, Vierthaler L, Tang W, et al FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol.2008 Dec;19(12):2342-50. Epub 2008 Aug 27.
[26]Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A.2010.107(1):407-412.
[27]Hofman-Bang J, Martuseviciene G, Santini MA, et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int.2010 Dec;78(11):1119-27.
[28]Nabeshima Y. Discovery of alpha-Klotho unveiled new insights into calcium and phosphate homeostasis. Proc Jpn Acad Ser B Phys Biol Sci.2009.85(3):125-141.
[29]Mendoza-Nunez VM, Ruiz-Ramos M, Sanchez-Rodriguez MA, Retana-Ugalde R, Munoz-Sanchez JL. Aging-related oxidative stress in healthy humans. Tohoku J Exp Med.2007.213(3): 261-268.
[30]Rakugi H, Matsukawa N, Ishikawa K, et al. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine.2007.31(1):82-87.
[31]姜靖,黄岚,赵晓辉等.Klotho对老龄小鼠内皮祖细胞修复损伤血管内膜的影响.中国药业.2009.18(24)：22-24.
[32]Zhou Z, Hu CP, Wang CJ, et al. Calcitonin gene-related peptide inhibits angiotensin II-induced endothelial progenitor cells senescence through up-regulation of klotho expression.Atherosclerosis.2010 Nov;213(1):92-101.
[33]Zhang H, Li Y, Fan Y, et al. Klotho is a target gene of PPAR-gamma.Kidney Int.2008 Sep;74(6):732-9. Epub 2008 Jun 11.
[34]Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun.2001.280(4):1015-1020.
[35]Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol.2009.20(2): 388-396.
[36]Haruna Y, Kashihara N, Satoh M, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A.2007.104(7):2331-236.
[37]Sugiura H, Yoshida T, Tsuchiya K, et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant.2005.20(12):2636-2645.
[38]Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med.2008.359(6):584-592.
[39]Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol.2008.102(1):47-53.
[40]Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med.2004.351(13):1296-1305.
[41]Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation.2003. 108(17):2154-2169.
[42]Tsujikawa H, Kurotaki Y, Fujimori T, et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol.2003; 17:2393-2403.
[43]Doi S, Zou Y, Togao O, et al. Klotho inhibits transforming growth factor-betal (TGF-betal) signaling and suppresses renal fibrosis and cancer metastasis in mice.J Biol Chem.2011 Mar 11;286(10):8655-65.
[44]Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm.2009.2009:137072.
[45]Hu MC, Shi M, Zhang J, et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int.2010.78(12):1240-1251.